216 results on '"Verges B"'
Search Results
2. Thyroïdites : où en est-on en 2019 ?
3. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
4. Mécanismes possibles des effets bénéfiques cardiovasculaires des inhibiteurs SGLT2
5. Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings
6. Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction
7. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry
8. IDF23-0544 Frequency of silent coronary artery disease in type 2 diabetics : preliminary results of a cross sectional study
9. Effects of anti-somatostatin agents on glucose metabolism
10. Prise en charge des dyslipidémies : quelles nouvelles recommandations?
11. Consensus statement on the management of dyslipidaemias in adults
12. Consensus statement on the management of dyslipidaemias in adults
13. The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients
14. Potential influence of Type A personality on plasma C-reactive protein levels in people with diabetes
15. Neuropathie induite par la thérapie chez les patients diabétiques : ne pas traiter trop vite !
16. Hyperglycémie induite par l’analogue de somatostatine pasiréotide au cours de la maladie de Cushing
17. Diabète secondaire aux inhibiteurs mTOR
18. Potential risks associated with increased plasma plant-sterol levels
19. Adverse effects and safety of SGLT-2 inhibitors
20. Une nouvelle indication du fénofibrate ? La rétinopathie diabétique, en Australie
21. Phytostérols, phytostanols, et risque cardiovasculaire
22. Lipides et diabète de type 1
23. Glycation des HDL et conséquences chez le patient diabétique
24. Effets cardiovasculaires des inhibiteurs de la DPP-4
25. Physical activity and type 2 diabetes. Recommandations of the SFD (Francophone Diabetes Society) diabetes and physical activity working group
26. Un nouveau système d’injection d’insuline « Daily Dose » : pour quel usage ?
27. Management of hyperglycaemia in Cushing's disease: Experts’ proposals on the use of pasireotide
28. Évaluation du niveau de littératie en santé chez les patients en essai clinique
29. Quelle place pour le traitement par pompe à insuline externe dans le diabète de type 2 ?
30. Effects of a home-based rehabilitation program in obese type 2 diabetics
31. Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes
32. Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome
33. Chronic kidney disease in type 2 diabetes patients in France: Prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes
34. Type 2 diabetes treatment intensification in general practice in France in 2008–2009: the DIAttitude Study
35. Quelle place pour les fibrates après l’étude ACCORD- Lipids ?
36. Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system
37. Outcome in AN adult patients: A 13-year follow-up in 484 patients
38. GLP-1 receptor agonists in NAFLD
39. After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?
40. High efficacy of screening for diabetes and prediabetes in cardiac rehabilitation after an acute coronary syndrome (ACS). The REHABDIAB study
41. Complications cardiovasculaires du diabète de type 1: Cardiovascular complications in type 1 diabetes
42. Risque cardiovasculaire résiduel du patient diabétique de type 2: Cardiovascular residual risk in patients with type 2 diabetes
43. Évaluation du risque cardiovasculaire chez le diabétique de type 2 et prescription d’une activité physique
44. L’intérêt démontré des statines chez les patients diabétiques de type 2: Evidence for statin use in patients with type 2 diabetes
45. Cardiovascular complications in type 1 diabetes mellitus
46. Are elderly patients with diabetes being overtreated in French long-term-care homes?
47. Les phytostérols : quels bénéfices ? quels risques ?: Plant sterol-enriched foods: Benefits and risks
48. Rôles des HDL sur l’endothélium: Endothelial actions of HDL
49. Le point sur l’apolipoprotéine C-1: Apolipoprotein C-1: Recent data
50. Insulinorésistance, diabète et infection par le virus de l’hépatite C
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.